PRNAF
Price:
$0.0036
Market Cap:
$29.01M
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.[Read more]
Industry
Biotechnology
IPO Date
2012-09-25
Stock Exchange
PNK
Ticker
PRNAF
According to Alterity Therapeutics Limited’s latest financial reports and current stock price. The company's current ROE is -182.58%. This represents a change of 279.32% compared to the average of -48.13% of the last 4 quarters.
The mean historical ROE of Alterity Therapeutics Limited over the last ten years is -57.84%. The current -182.58% ROE has changed 215.67% with respect to the historical average. Over the past ten years (40 quarters), PRNAF's ROE was at its highest in in the December 2014 quarter at -1.72%. The ROE was at its lowest in in the June 2024 quarter at -91.44%.
Average
-57.84%
Median
-50.82%
Minimum
-138.60%
Maximum
-15.05%
Discovering the peaks and valleys of Alterity Therapeutics Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 129.01%
Maximum Annual ROE = -15.05%
Minimum Annual Increase = -57.46%
Minimum Annual ROE = -138.60%
Year | ROE | Change |
---|---|---|
2024 | -138.60% | 129.01% |
2023 | -60.52% | 67.09% |
2022 | -36.22% | -27.91% |
2021 | -50.24% | -47.32% |
2020 | -95.37% | 27.97% |
2019 | -74.53% | 44.99% |
2018 | -51.40% | 61.45% |
2017 | -31.84% | 29.20% |
2016 | -24.64% | 63.78% |
2015 | -15.05% | -57.46% |
The current ROE of Alterity Therapeutics Limited (PRNAF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-78.45%
5-year avg
-76.19%
10-year avg
-57.84%
Alterity Therapeutics Limited’s ROE is greater than Genprex, Inc. (-318.57%), less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), greater than Greenwich LifeSciences, Inc. (-153.95%), greater than Cognition Therapeutics, Inc. (-118.11%), greater than Gracell Biotechnologies Inc. (-37.20%), less than Galectin Therapeutics Inc. (0%), less than Northwest Biotherapeutics, Inc. (67.01%), less than CEL-SCI Corporation (133.00%), greater than Tonix Pharmaceuticals Holding Corp. (-233.88%), greater than Jaguar Health, Inc. (-158.27%), greater than Acasti Pharma Inc. (-354.93%), greater than Diffusion Pharmaceuticals Inc. (-18.84%), greater than iBio, Inc. (-55460.19%), greater than Vaxart, Inc. (-145.25%), greater than Novavax, Inc. (-114.19%), less than Ocugen, Inc. (43.70%), greater than CohBar, Inc. (-139.20%), greater than Rain Therapeutics Inc. (-58.44%), greater than Viking Therapeutics, Inc. (-81.52%), greater than TG Therapeutics, Inc. (-12.73%), greater than X4 Pharmaceuticals, Inc. (-38.21%), less than PDS Biotechnology Corporation (32.93%), greater than Madrigal Pharmaceuticals, Inc. (-137.06%), greater than null (-71.78%),
Company | ROE | Market cap |
---|---|---|
-318.57% | $5.23M | |
664.92% | $33.39M | |
-153.95% | $172.06M | |
-118.11% | $19.04M | |
-37.20% | $989.87M | |
0% | $157.25M | |
67.01% | $314.56M | |
133.00% | $52.80M | |
-233.88% | $19.46M | |
-158.27% | $9.61M | |
-354.93% | $34.17M | |
-18.84% | $8.98M | |
-55460.19% | $24.40M | |
-145.25% | $164.89M | |
-114.19% | $1.46B | |
43.70% | $275.62M | |
-139.20% | $1.42M | |
-58.44% | $44.01M | |
-81.52% | $7.04B | |
-12.73% | $3.77B | |
-38.21% | $89.59M | |
32.93% | $118.93M | |
-137.06% | $7.23B | |
-71.78% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alterity Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Alterity Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Alterity Therapeutics Limited's ROE?
How is the ROE calculated for Alterity Therapeutics Limited (PRNAF)?
What is the highest ROE for Alterity Therapeutics Limited (PRNAF)?
What is the 3-year average ROE for Alterity Therapeutics Limited (PRNAF)?
What is the 5-year average ROE for Alterity Therapeutics Limited (PRNAF)?
How does the current ROE for Alterity Therapeutics Limited (PRNAF) compare to its historical average?